Argireline
Acetyl Hexapeptide-8 (Acetyl Hexapeptide-3)
Clinical trials showed mixed results. Benefits were seen on some measures but not others.
A topical skincare ingredient designed to relax facial muscles and reduce the appearance of wrinkles. Human studies show mixed results -- one small trial found significant wrinkle reduction, while another independent study found no significant effect.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Argireline has an excellent safety profile for topical use across all published studies. The original study reported no in vivo oral toxicity and no primary irritation at high doses (PMID 18498523). In the Henseler 2023 split-face study, no significant adverse events, allergic reactions, or skin irritation were reported over 4 weeks (PMID 38024099). In the NIH blepharospasm trial (NCT00942851), 4 subjects (2 active, 2 placebo) experienced minor self-limited eyelid irritation. In the follow-up NIH trial (NCT01750346), one participant in the 0.05% arm experienced puffiness of lower eyelid, and one placebo subject had eyelid tingling. No serious adverse events were attributed to the study drug. Cytotoxicity testing showed anti-proliferative effects only at concentrations 18-10,000 fold higher than doxorubicin, depending on cell type (PMID 24644551). Acute oral LD50 is greater than 2000 mg/kg (PMID 18498523). Notably, a case report documented Mycobacterium abscessus nodules and abscesses after facial argireline injection (not topical use), requiring 5 months of clarithromycin plus moxifloxacin therapy; this represents injection-specific risk, not topical use risk (PMID 33748252). community users have anecdotally reported headaches with high-concentration (10%) use, but this is not documented in clinical literature.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-26]